Trial Profile

A trial of SB 913 for the treatment of beta-thalassaemia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Jan 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SB 913 (Primary)
Indications Beta-thalassaemia
Focus Adverse reactions

Most Recent Events

06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
05 May 2016 New trial record
02 May 2016 According to a Sangamo BioSciences media release, the company plans to submit investigational new drug (IND) application for SB 913 for beta-thalassaemia in the first half of 2016.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com